Xiamen's Generic Memantine, Donepezil Receives Approval in the U.S.
(Reuters) - AbbVie Inc has agreed to pay $54.4 million to settle a proposed class action brought by health plans that claim they overpaid for the Alzheimer's drug Namenda because of illegal settlements that delayed the launch of generic versions of the drug.
Xiamen's Generic Memantine Hydrochloride Receives Approval in the U.S.
Hetero's Generic Memantine Hydrochloride Receives Approval in the U.S.
Judge opts for jury trial in Alzheimer`s drug case
Polygen Pharms Generic Memantine Hydrochloride Receives Approval in US
Medley Pharmaceuticals's Generic Daptomycin Receives Approval in US
Enforcement Report - Week of May 20, 2020
Ningbo's Generic Memantine Hydrochloride Receives Approval in US